| Name | Title | Contact Details |
|---|
Pacific Artisan Labs holds our commitment to quality and passion for the latest technology at the core of our process. Our independent lab network is able to be drastically differently, move nimbly, and respond to what our customers need. We build long-term relationships with our partners and continue to refine our techniques, tools, and lenses as true artistic expressions of skill with a goal to improve the practices we work with and the patients they serve. Guided by a passion for the craft of lens design and desire to do things differently, Brandon Butler founded Pacific Artisan Labs early in 2018. His rich experience in the industry and focus on quality makes him uniquely equipped to serve as President and CEO. United by our mission to team up with optometrists and ophthalmologists in their pursuit of excellence, our lab technicians create the quality difference in our lenses. PAL`s lab staff includes some of the most talented artisans in the optical industry. Our team is what separates PAL from every other lab in the network. Any lab can have great designs, top-notch equipment, and good prices; but without the best talent, the latest tech is pointless. That`s why PAL only works with the best of the best. We`re an independent lab and our culture reflects that breakaway from the corporate mold. Innovative and creative, our team joined PAL to contribute to the maker revolution. We`re curious artists, skilled technicians, driven data analysts, and inventive strategists.
Sightpath Medical is a Minneapolis, MN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Gentis Inc is a Wayne, PA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
BioSig Technologies, Inc. (NASDAQ: BSGM) is a medical device company that is developing a proprietary biomedical signal processing technology platform to address an unmet technology need in the rapidly growing $4.6+ billion electrophysiology (EP) marketplace. Led by a proven management team, world-class Board of Directors and Scientific Advisory Board, Los Angeles-based BioSig Technologies is preparing to commercialize its PURE EP™ System. The PURE EP™System is a surface electrocardiogram (ECG) and intracardiac multichannel recording and analysis system designed to assist electrophysiologists in making crucial clinical decisions in real-time by acquiring and displaying high-fidelity cardiac signal recordings even at undetectable levels (until now) with high accuracy to help identify appropriate catheter ablation targets - areas of tissue to destroy that create a heart rhythm disturbance (arrhythmia). BioSig aims to deliver technology to improve upon catheter ablation treatments for the prevalent and potentially deadly arrhythmias, Atrial Fibrillation and Ventricular Tachycardia. PURE EP™ System is an innovative platform, offering potential benefits over current technologies including increased accuracy, reduced noise and interference, clinical information previously not available and potential elimination of the need for repeat procedures. BioSig has partnered with Minnetronix on technology development and has received FDA 510(k) clearance for the PURE EP™ System in August 2018. BioSig Technologies, Inc. is a Nasdaq company: NASDAQ:BSGM.
Lechnologies Research is a Sussex, WI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.